Signal Management & Benefit-Risk
Explore all topics, guides, and frameworks related to Signal Management & Benefit-Risk.
Articles in this section
26- How to Read an EMA Referral From a Pharmacovigilance Perspective Explains how to reconstruct an EMA referral chronologically and distinguish the initiating concern, evidence assessment, PRAC recommendation, CHMP or CMDh step, European Commission decision and final implementation. Read Article →
- Emerging Safety Issue Assessment: Evidence, Urgency and Regulatory Decision-Making Explains how an MAH should reason from a new safety concern to an emerging-safety-issue decision, distinguishing ESI assessment from ordinary signal management and separating GVP guidance from recommended operational practice. Read Article →
- What Is a Safety Signal? Explains what a safety signal is, why a signal is a hypothesis rather than proof of causality, how signals arise from different evidence sources, and where signal validation and assessment fit in the wider safety-evaluation process. Read Article →
- Signal Validation in Pharmacovigilance Explains the purpose, regulatory framework, scientific criteria and documentation of signal validation, including how to handle weak data, known risks, multiple sources and uncertainty without relying on arbitrary thresholds or mandatory committee structures. Read Article →
- Signal Tracking and Documentation Explains what signal-management documentation must achieve, how records should connect across the signal lifecycle, how tracking systems support oversight, and how to distinguish regulatory traceability needs from organisation-specific templates and sign-offs. Read Article →
- Signal Prioritisation in Pharmacovigilance Explains why prioritisation is distinct from causality assessment, which factors influence urgency, how expert judgement and structured methods can be combined, and why fixed numerical scoring thresholds are not universal regulatory requirements. Read Article →
- Signal Management Provides the section-level framework for signal management and explains how safety information progresses from a hypothesis to a documented scientific conclusion and, where necessary, regulatory or risk-management action. Read Article →
- Signal Management SOPs Explains how a signal-management SOP should translate regulatory requirements into an organisation-specific controlled process without hard-coding unnecessary committees, arbitrary timelines or obsolete EudraVigilance assumptions. Read Article →
- Signal Management Metrics Explains how signal-management metrics should be designed, calculated and interpreted so they provide reliable evidence about workload, timeliness, quality and control without turning arbitrary internal targets into regulatory requirements. Read Article →
- Signal Management Oversight Explains how signal-management oversight differs from operational execution, how QPPV, process owners, quality and management obtain assurance, and how evidence from metrics, audits, vendors and individual signals is integrated. Read Article →
- Signal Management KPIs Explains how signal-management KPIs support oversight without turning arbitrary internal targets into regulatory requirements, and how useful indicators should connect measurement to risk, interpretation and action. Read Article →
- Signal Management Governance Explains how governance turns signal-management science into consistent, traceable decisions without imposing unnecessary committees or rigid approval structures that are not regulatory requirements. Read Article →
- Signal Management for QPPVs Explains what the QPPV needs to know and oversee across the signal lifecycle without confusing system oversight with routine operational ownership of detection or assessment activities. Read Article →
- Signal Management Committees Explains the role of signal management committees within an MAH pharmacovigilance system, distinguishing regulatory requirements from optional organisational structures and showing how committees support challenge, escalation, traceability and QPPV oversight. Read Article →
- Signal Management During Pharmacovigilance Inspections Explains how an inspector can test the effectiveness of the signal-management system from detection and validation through assessment, action and closure, and distinguishes inspection evidence from organisation-specific preparation practices. Read Article →
- Signal Detection in Pharmacovigilance Explains how potential safety signals are identified from complementary data sources, how qualitative review and disproportionality methods differ, how current EU requirements changed after Implementing Regulation (EU) 2025/1466, and how detection feeds into validation and assessment. Read Article →
- Signal Management Audit Readiness Explains what auditors and inspectors need to see in a signal-management system, how lifecycle traceability works, which evidence matters, how QPPV and governance oversight should be demonstrated, and which readiness controls are recommended rather than mandated. Read Article →
- Signal Assessment in Pharmacovigilance Explains how a validated or confirmed safety signal is scientifically assessed using case evidence, clinical and epidemiological data, literature, mechanism and exposure information, and how conclusions are translated into proportionate pharmacovigilance or regulatory action. Read Article →
- PRAC Signal Management Explains the relationship between MAH signal management, EudraVigilance, Member State and EMA activities, PRAC scientific assessment, requests for information, published signal recommendations and implementation of regulatory outcomes. Read Article →
- EVDAS and Signal Detection in Pharmacovigilance EVDAS is the analytical interface through which authorised users interrogate EudraVigilance data. This article explains how to read eRMRs and disproportionality outputs, how to move from a statistical observation to a clinically reasoned signal decision, and how EVDAS should be integrated into the MAH's signal-management process after the 2025 regulatory changes. Read Article →
- EudraVigilance Signal Detection EudraVigilance is an important source of suspected adverse reaction information, but its role in MAH signal management changed materially in 2025. This article explains the current legal requirement to monitor EudraVigilance and use its data with other sources, how EVDAS outputs support detection and evaluation, and how statistical findings are converted into clinically reasoned signal decisions. Read Article →
- Emerging Safety Issues in Pharmacovigilance An emerging safety issue is a safety concern of such urgency and seriousness that normal handling cannot be allowed to delay regulatory attention. This article explains how the EU GVP framework defines and manages emerging safety issues, how they differ from routine signals and other urgent safety concepts, what information should be notified to EMA and relevant competent authorities, and how organisations should govern rapid assessment without inventing internal thresholds or timelines as regulatory requirements. Read Article →
- Disproportionality Analysis in Pharmacovigilance Disproportionality analysis is a statistical screening approach used to identify product-event combinations reported more often than expected within spontaneous-report databases. This article explains how the main measures are calculated and interpreted, why a signal of disproportionate reporting is not proof of causality or incidence, how EudraVigilance uses the reporting odds ratio, and how quantitative findings should be integrated with clinical review and other safety evidence. Read Article →
- Data Sources for Signal Management Signal management depends on integrating multiple data sources with different strengths, biases and levels of evidentiary value. This article explains how spontaneous reports, regulatory databases, literature, clinical trials, observational studies, real-world data, registries, product information and mechanistic evidence contribute to signal detection, validation and assessment, and how pharmacovigilance professionals should govern source quality, traceability and interpretation. Read Article →
- Common Signal Management Failures A practical guide to detection, validation, assessment, escalation, documentation, oversight and inspection evidence. Read Article →
- Benefit-Risk Evaluation in Pharmacovigilance A practical guide to benefit-risk reasoning in signals, PSURs, risk management, regulatory decisions and QPPV governance. Read Article →